15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with advanced hepatocellular carcinoma (HCC) have few treatment options. Thymalfasin (thymosin α-1) is an immunomodulator that may increase response to ablative therapy through direct anti-tumor action or enhanced protection against infections. We compared transarterial chemoembolization (TACE) plus thymalfasin with TACE alone for unresectable HCC.

          Related collections

          Author and article information

          Journal
          Hepatol Int
          Hepatology international
          Springer Nature America, Inc
          1936-0533
          1936-0533
          Sep 2009
          : 3
          : 3
          Article
          9132
          10.1007/s12072-009-9132-3
          2748379
          19669251
          b2e27495-ce20-481c-9627-e72164af5a6e
          History

          Comments

          Comment on this article